An understanding of the natural history and likely viral characteristics determine the need for treatment, the likelihood of response to treatment, and the toleroutcome of infection is prerequisite for the sensible management of patients with chronic hepatitis virus ability of treatment.
The acceptability and reputation of antiviral infection. Antiviral treatment should be considered for patients with chronic hepatitis B virus (HBV) and therapy for chronic viral hepatitis depends on appropriate patient selection. hepatitis C virus (HCV) infection. Hepatitis D virus (HDV, delta virus) infection is uncommon, so its treatSustained inhibition of viral replication is the principal goal of antiviral therapy. Profound inhibition of ment is not considered here.
In developing countries, HBV infection is usually replication can now be achieved for the majority of patients with chronic HBV infection, and for many acquired at birth or pre-school. For many years, viral replication is unbridled by tolerant immune response, with chronic HCV infection. Reflecting high virus production rates with rapid clearance from serum, and liver inflammation is mild or absent despite high serum titres. A phase of tolerance is less frequently inhibition of replication effects a prompt reduction of serum virus titre.1,2 Therefore, measurement of serum experienced by those who acquire infection at a later age, the usual situation in developed countries. Loss genomic titre with sensitive quantitative assays that have a broad detection range is prerequisite for the or absence of tolerance is associated with the development of hepatitis, which reflects elimination of development of treatment strategies, and will become an essential component of routine patient maninfected hepatocytes. Serum viral titre diminishes as infected hepatocytes are cleared. For the majority of agement.
Ideally, sustained inhibition of viral replication will patients, severe liver damage is not sustained during brisk transition from high-level to low-level viral repbe achieved by treatment of short duration. Sustained inhibition implies that inhibition of replication perlication. Cirrhosis, liver failure and liver cancer most often ensue when hepatitis and high levels of replicasists after treatment withdrawal. Such response minimizes the morbidity and expense of antiviral therapy. tion persist for years. Therefore, significant hepatitis in the context of high serum titres identifies HBVShort-term treatment of chronic HBV infection with alpha-interferon (IFN) may achieve sustained infected patients who are suitable for antiviral therapy.
inhibition of viral replication in a fraction of treated patients. Sustained inhibition is predicted by the More controversial is the selection of HCVinfected patients for antiviral therapy. It is recognized clearance of HBeAg from serum, usually associated with the appearance of antibodies to HBeAg (antithat many patients progress to cirrhosis after a prolonged period of chronic hepatitis. Though significant HBe), during treatment.3 Therefore, HBeAg seroconversion is recognized as a primary treatment objective. liver disease is seldom observed when viral RNA is undetectable in serum, the prognosis of viraemic Predictors of IFN-induced HBeAg seroconversion include declining pre-treatment serum viral titre and patients is not clearly related to serum viral titre (or to genotype). Non-viral factors (patient gender, age at active hepatitis.4,5 IFN-induced seroconversion is probably associated with an improved long-term clintime of infection, concomitant alcohol consumption) may be more important determinants of prognosis.
ical outcome, with reduced risk for the development of liver failure. The selection of patients for antiviral therapy should consider the following factors. Treatment may not be Currently, the response of chronic HBV infection to treatment with nucleoside (and nucleotide) anaindicated when the liver biopsy is nearly normal despite long duration of infection, when serum transamlogues is being evaluated. Candidate drugs include lamivudine, famciclovir, lobucavir and adefovir. Of inases are persistently normal, when there is concomitant alcohol abuse and if serious non-hepatic these, lamivudine has reached the most advanced stage of clinical assessment, and important lessons co-morbid disease is present. Therefore, patient and have been learned. Lamivudine inhibits reverse ciated with a rise in serum viral titre, and with renewed hepatitis. There is no proven benefit in sustranscriptase and prevents elongation of the proviral DNA chain (HBV is a DNA virus that replicates via taining lamivudine treatment beyond the time of emergence of the resistant species. Cessation of lamian RNA intermediate). Lamivudine has excellent oral bioavailability and is well tolerated in patients with vudine after the emergence of resistant species is associated with eventual reversion of serum dominearly and advanced liver disease.6,7 Treatment effects dose-dependent inhibition of viral replication, and at ance to the wild-type species. Our observations, and published preliminary correspondence, suggest that least 2 log 10 decline of serum viral titre is observed at doses of 100 mg per day.8 In phase 3 studies, treatlamivudine-resistant HBV species are unresponsive to famciclovir in the majority of cases.14 In vitro data ment of 52 weeks duration achieved sustained HBeAg seroconversion for 16-20% of treated suggest that lamivudine-resistant species may be susceptible to treatment with lobucavir or adefovir.15 patients.9,10 In the same studies, spontaneous seroconversion was observed for 4% of patients, IFNTherefore, suppressive antiviral therapy might be administered until HBeAg seroconversion is achieved induced seroconversion was observed for 22%, and the combination of IFN with lamivudine achieved or until drug resistance emerges. Akin to developments in the treatment of HIV infection, it seems 25% sustained seroconversion. Therefore, short-term treatment with lamivudine may achieve sustained likely that combination therapy including more than one nucleoside (or nucleotide) analogue will be inhibition of replication, its efficacy is comparable to that of IFN and it has a more favourable side-effect developed. The challenge is to identify regimens that are safe, well-tolerated and which require multiple profile. Unfortunately, the majority of patients treated with IFN and/or lamivudine do not achieve HBeAg viral mutations to confer resistance. Under these circumstances, indefinite inhibition of viral replication seroconversion during treatment, and viral replication resumes when treatment is withdrawn.
with amelioration of hepatitis might be achieved in the absence of HBeAg seroconversion. If seroconversion is not achieved, prolongation of lamivudine treatment may maintain suppression of IFN is the only medication licensed for the treatment of HCV infection. Once again, the aim of treatviral replication until drug-resistant species emerge. Resistant species require a valine or isoleucine substiment is to achieve sustained (i.e. persisting after treatment has stopped) clearance of viral RNA from tution for methionine at amino acid position 552 of the viral polymerase.11 Valine 552 is always associated serum. The standard regimen of 3 mega-units thrice weekly achieves this objective for a minority of with a methionine for leucine substitution at position 528. Lamivudine monotherapy of HIV infection is patients. Virological response is usually associated with normalization of serum transaminases. associated with the rapid emergence of resistant HIV species with similar polymerase mutations. In conVirological and biochemical responses may be observed for a significant proportion of treated trast to the observed rate of emergence of resistant species during lamivudine treatment of HIV infection, patients during therapy, but many relapse after treatment withdrawal, and sustained responses are lamivudine-resistant HBV species are slow to emerge during treatment of chronic hepatitis, and only 14% observed in few. Meta-analysis of randomized trials suggests that a higher IFN dose and longer duration of treated patients have serum dominance of the resistant genotype after 12 months therapy.9 In the study of treatment may substantially improve the sustained response rate.16 However, higher doses may be assoof Lai et al., drug resistance was first observed after 24 weeks of treatment.9 Of course, the incidence of ciated with increased patient morbidity, diminished treatment tolerance, and patient non-compliance. Of resistance increases with duration of treatment,12 and resistance may be an inevitable development when course, treatment cost relates to total administered dose. Therefore, alternative treatment regimens need the pre-treatment viral replication rate is high (as it is for the majority of patients with treatment-requiring to consider cost-benefit analysis, and response rates should refer to the intent-to-treat patient population. viral hepatitis). It seems most likely that the resistant species exist in the patient as part of the viral quasiPre-treatment virus and patient characteristics that predict response/non-response to IFN monotherapy species prior to lamivudine exposure. These resistant species exist because viral polymerase fidelity is have been identified.17,18 Most important appear to be HCV genotype and serum genomic titre, and prespoor, and the replication rate is high.1 The resistant species is biologically less fit than the wild-type in ence/absence of cirrhosis. Sustained response is most likely for non-cirrhotic patients with low viral titre the absence of lamivudine,13 but is the fitter species during lamivudine treatment. Factors affecting the and genotype other than type 1. Cirrhotic patients with high titres of genotype 1 rarely respond. Despite rate of emergence have yet to be elucidated, though the severity of the underlying hepatitis (a measure of the clear association of these factors with likelihood of treatment response, they lack predictive accuracy the rate of generation of susceptible hepatocytes) may be important. Emergence of resistant species is assoand should not be used to identify or exclude treat-ment candidates. Indeed, the early virological doses. In addition, maximum reduction of serum viral titre is observed 24 h post-dose, and serum titre then response during therapy is probably the best predictor of treatment response. Current practice favours the rises during the second post-treatment day. Therefore, greater inhibition may be observed with daily rather administration of antiviral therapy to most patients with HCV viraemia and abnormal liver function tests, than thrice-weekly treatment schedules. I have attempted to highlight the recent significant then withdrawal of treatment if viral RNA persists in serum despite 12 weeks of therapy. Persistence at that and impressive advances in the treatment of chronic viral hepatitis. Profound inhibition of viral replication time identifies patients with little hope of sustained response. The proportion of treated patients who is associated with normalization of serum transminases and with a favourable evolution of liver hisachieve early serum viral clearance includes those who will achieve sustained response and also those tology. For many patients, treatment of short duration can achieve sustained inhibition of viral replication. who will experience virological relapse at conclusion of therapy. Probably, IFN regimens using higher Attention needs to be focused on (a) the development of combination therapy for the prolonged inhibition doses of longer duration principally affect relapse rate in those who enjoy an initial virological response.
of HBV replication without the emergence of resistance, and (b) improved protocols for the treatment of Phase 3 studies evaluating the combination of IFN with the nucleoside analogue ribavirin were recently HCV-infected patients with advanced disease and unfavourable virological characteristics. concluded.19,20 The results are impressive, and the combination appears to constitute a major advance D. Mutimer Liver and Hepatobiliary Unit over IFN monotherapy for the treatment of chronic HCV. Studies principally included non-cirrhotic Queen Elizabeth Hospital Birmingham patients, and patients with advanced cirrhosis and portal hypertension were excluded. Therefore, conclusions derived from analysis of these studies concerning efficacy and safety are restricted to non-
